BIIB Related Options
-
Biogen Idec (BIIB) volatility flat shares near record high
-
Biogen Idec (BIIB) volatility near historic lows into Goldman upgrade to Buy
-
Goldman Sachs Recommends Buying Options Ahead of Healthcare Conference
-
Call option volume increases: TQNT BIIB SWN HOG
-
Put option volume increases: BIIB CBG TXT RIMM RAH
-
Put option volume increases: REE YOKU HTZ BIIB
-
Biogen Idec (BIIB) volatility elevated into UBS upgrade to Buy
-
Biogen (BIBB) volatility low; shares rally 20% on positive MS drug data and profit up 35%
-
Biogen Idec (BIIB) volatility deceases as shares rally 7% on positive top-line results
-
Biogen Idec (BIIB) volatility low; shares up 6% on positive top-line results
-
Biogen (BIIB) volatility low on tight three-month trading range
-
Biogen (BIIB) volatility flat as shares trend lower into Q4 EPS and outlook
-
Biogen (BIIB) August call volume and volatility increases after EPS
-
Biogen (BIIB) volatility elevated on report of Sanofi-Aventis buyout
-
Biogen (BIIB) volatility up; shares trend lower into ASCO
-
Biogen (BIIB) volatility at 30 into EPS and rituxan sales outlook
-
Biogen (BIIB) volatility is flat after sharp five-month rally
-
Biogen (BIIB) calls active on 22K contracts as shares trend higher
-
Biogen Idec (BIIB) March volatility flat into EPS and outlook
-
Biogen Idec (BIIB) volatility stays low on active options volume
-
Biogen Idec (BIIB) option volume lightens as volatility stays low a day after buyout chatter
-
Biogen Idec (BIIB) August volatility at 47 into EPS
-
Biogen Idec (BIIB) volatility low into JNJ $1B investment in Elan
-
Biogen Idec (BIIB) volatility low into 10th PML case
-
Biogen Idec (BIIB) May volatility at 58; July at 51 into EPS and Icahn pressure
-
Biogen Idec (BIIB) April volatility at 55 into EPS and Outlook
-
Biogen Idec (BIIB) volume, volatility & share price spikes on renewed M&A chatter
-
Biogen Idec (BIIB) volatility flat at 52 after R&D day
-
Biogen Idec (BIIB) volume and volatility Flat into EPS
-
Biogen Idec (BIIB) volatility at 54 into EPS and Outlook
-
Biogen Idec (BIIB) January volatility at 72
-
Biogen (BIIB) volatility Flat; shares down on Tysabri link to brain infection
-
Biogen (BIIB) volatility Elevated collapses as shares rally on EPS
-
Biogen (BIIB) volatility Elevated as shares rally on Q4 financials
-
Biogen (BIIB) volatility Elevated at 50 as shares rally 5%
-
Equity option family volume leaders in first 30-minutes of Trading: MBI BIIB RIMM ORCL
-
Equity option family volume leaders in first 30-minutes of Trading: C WM LEH BIIB
-
Biogen (BIIB) volatility Elevated; BIIB down 28%, announces Continue Present Course
-
Biogen (BIIB) volatility stays Elevated on expectations of Evaluation
-
Biogen (BIIB) volatility Up into 3Q revenues of $789m, BIIB evaluating better value for its stockholders
-
Biogen volatility Elevated as BIIB consider Sale
-
Biogen (BIIB) volatility Elevated as BIIB Evaluates better value for its Stockholders
-
Biogen (BIIB) volatility Elevated at 38 as BIIB near 32-month high
-
Biogen (BIIB) volatility at 32 as BIIB near 29-month high
-
Biogen Idec (BIIB) implied volatility suggests less risk Dutch tender offer
-
Biogen Idec (BIIB) option implied volatility at 25 into Rituxan Safety Warning
-
American Society of Clinical Oncology (ASCO) participants June stock option implied Volatility - Part 3
-
Biogen Idec-BIIB option implied volatility at high end of range into Tysabri FDA committee
-
Biogen Idec-BIIB March options active into Tysabri FDA committee meeting
-
Biogen Idec-BIIB March option implied volatility increases into FDA committee
Back to BIIB Stock Lookup
